Erythropoietin Stimulating Agents Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types), By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications), By Region & Competition, 2020-2030F

Market Overview

Global Erythropoietin Stimulating Agents Market was valued at USD 7.45 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.14% through 2030F. Endogenous erythropoietin (EPO), a glycoprotein hematopoietic hormone, is produced by the renal tubules. It directs and regulates the erythropoiesis process in the bone marrow. Erythropoietin stimulating agents (ESAs) can speed up the proliferation of red blood cells. Erythropoietin-stimulating medications are suggested for the treatment of anaemia brought on by chemotherapy, HIV, and chronic kidney failure. During difficult surgical procedures, low red blood cell counts can also be treated with these stimulants. Anemia is a common medical condition associated with various underlying diseases, such as chronic kidney disease (CKD), cancer, HIV/AIDS, and inflammatory disorders. The prevalence of these conditions contributes to the demand for ESA therapies to manage anemia. For instance, according to WHO 2025, anemia is a major global health concern, especially among young children, pregnant women, and menstruating girls and women. It disproportionately affects rural, low-income, and uneducated populations in low- and lower-middle-income countries. In 2019, anemia caused 50 million healthy life years lost, mainly due to iron deficiency, thalassaemia, sickle cell trait, and malaria. The global population is aging, and older adults are more susceptible to conditions that can lead to anemia. As the elderly population grows, the demand for ESA treatments may increase.

Advances in cancer diagnosis and treatment have led to more cancer patients receiving chemotherapy and radiation therapy. These treatments can induce anemia, creating a greater need for ESA drugs. Clinical guidelines issued by medical associations and healthcare organizations often recommend ESA therapy for managing anemia in specific patient populations. These guidelines influence treatment decisions. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a pivotal role in approving ESA products for various indications, thereby expanding their use. Patient advocacy groups and organizations raise awareness about anemia-related conditions and advocate for improved access to ESA therapies, leading to increased patient demand. The introduction of biosimilar versions of ESA products has created competition in the market, potentially reducing treatment costs and expanding access to these therapies.

Key Market Drivers

Advancements in Oncology

Chemotherapy-induced anemia is a common side effect of cancer treatment, leading to fatigue and reduced quality of life. ESAs like Epoetin Alfa and Darbepoetin Alfa have been used to manage CIA. Advancements in oncology have led to the development of more effective and targeted chemotherapy regimens, which may reduce the severity of anemia associated with treatment. Historically, ESAs have been associated with safety concerns, particularly an increased risk of cardiovascular events in cancer patients. Advances in oncology research have contributed to a better understanding of the safety profiles of ESAs and the identification of patient subgroups that may benefit from ESA therapy while minimizing risks. Advances in oncogenomics and personalized medicine have led to more individualized cancer treatment plans. This can include tailoring ESA therapy based on a patient's genetic profile and underlying cancer type, optimizing treatment outcomes while minimizing risks.

Oncology treatment guidelines from organizations like the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) provide recommendations on the use of ESAs in cancer patients. These guidelines are updated regularly to reflect the latest research findings and advancements in cancer care. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have become increasingly important in oncology. These therapies are designed to specifically target cancer cells while sparing healthy ones. As a result, some targeted therapies may have a reduced impact on red blood cell production and anemia, potentially reducing the need for ESAs in certain cases. Oncologists may explore combinations of treatments to improve cancer outcomes. The use of ESAs in conjunction with other supportive care measures, such as blood transfusions or iron supplementation, can be tailored to the specific needs of cancer patients. Ongoing clinical trials in oncology often include investigations into the use of ESAs in combination with new cancer therapies. These trials aim to identify optimal treatment strategies and improve patient outcomes. The development and approval of biosimilar versions of ESAs have introduced more cost-effective alternatives to the market. Biosimilars may play a role in reducing the economic burden of ESA therapy in oncology. Advancements in oncology have led to improved strategies for monitoring patients receiving ESA therapy, including regular assessment of hemoglobin levels and cardiovascular risk factors. This allows for early intervention and risk mitigation. This factor will help in the development of Global Erythropoietin Stimulating Agents Market.

Growth in Aging Population

Anemia is more common in older adults due to various factors, including chronic diseases, nutritional deficiencies, and reduced bone marrow function. For instance, according to WHO 2024, by 2030, one in six people globally will be aged 60 or older, with this population growing from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and above is expected to double, reaching 2.1 billion worldwide. As people age, their risk of developing anemia or experiencing a worsening of pre-existing anemia increases. Older adults are more likely to have chronic health conditions such as chronic kidney disease, cancer, and inflammatory disorders. Many of these conditions can lead to anemia. ESAs are commonly used to manage anemia associated with these chronic diseases in older patients. Aging can lead to a decline in the body's natural production of erythropoietin, the hormone that stimulates the production of red blood cells in the bone marrow. This can result in a decreased ability to respond to anemia effectively, making ESAs a valuable treatment option. Anemia can cause symptoms such as fatigue, weakness, and shortness of breath, negatively impacting the quality of life in older adults. ESAs can help alleviate these symptoms and improve overall well-being, making them a desirable treatment option for elderly patients.

In older adults, reducing the need for blood transfusions is often a goal of treatment. ESAs can be used to raise hemoglobin levels, reducing transfusion dependence and associated risks in elderly patients. Medical guidelines often recommend the use of ESAs for managing anemia in older adults, particularly when anemia is related to specific chronic conditions. Healthcare providers may follow these guidelines when treating elderly patients. As populations age, there is an increased focus on improving the overall health and well-being of older adults. Managing anemia is part of supportive care for the aging population, aligning with efforts to enhance their quality of life. In many developed countries, older adults have access to healthcare systems that can provide them with ESA treatments. This accessibility contributes to the demand for ESA therapy among the aging population. As healthcare expenditure increases with aging populations, resources are allocated to addressing the healthcare needs of older adults, including the management of anemia with ESAs. This factor will pace up the demand of Global Erythropoietin Stimulating Agents Market.

Increasing Prevalence of Anemia-Related Conditions

Anemia is a condition characterized by a deficiency of red blood cells or hemoglobin, which can lead to symptoms such as fatigue, weakness, and reduced oxygen-carrying capacity in the blood. Anemia is a common health issue worldwide, affecting millions of people. For instance, according to WHO 2025, anemia is a major public health issue, especially among young children, pregnant and postpartum women, and menstruating girls. It is most prevalent in low- and lower-middle-income countries, particularly in rural, low-income, and uneducated populations. Globally, it affects 40% of young children and 30–37% of women. The prevalence is particularly high in certain populations, including individuals with chronic diseases such as chronic kidney disease (CKD), cancer, HIV/AIDS, and inflammatory disorders. Anemia is a well-recognized complication of CKD (Chronic Kidney Disease), especially in advanced stages. As the prevalence of CKD increases, driven by factors like aging populations and rising rates of diabetes and hypertension, there is a growing need for ESA therapy to manage anemia in CKD patients. Cancer and cancer treatments can lead to anemia, a condition known as chemotherapy-induced anemia (CIA). The prevalence of cancer is on the rise globally, and as more individuals undergo cancer treatments, the demand for ESAs to manage CIA also increases. Older adults are more susceptible to anemia due to factors such as reduced bone marrow function, nutritional deficiencies, and chronic illnesses. As the global population continues to age, the prevalence of age-related anemia is expected to rise, contributing to the demand for ESA therapy. Conditions like rheumatoid arthritis and inflammatory bowel disease can lead to chronic inflammation, which can contribute to anemia. The prevalence of these inflammatory disorders is significant, and ESA therapy may be necessary for managing anemia in affected patients.

Anemia is a common complication in individuals living with HIV/AIDS. As the global population living with HIV/AIDS continues to grow, the demand for ESA therapy to address HIV-related anemia remains substantial. Certain nutritional deficiencies, such as iron, vitamin B12, and folate deficiencies, can lead to anemia. Although nutritional deficiencies can be addressed with supplementation and dietary changes, some individuals may still require ESAs, especially if the deficiency is severe or persistent. Patients on hemodialysis for end-stage renal disease often experience anemia due to the loss of erythropoietin-producing capacity in the kidneys. The prevalence of hemodialysis-dependent patients contributes to the demand for ESA therapy. Advances in medical diagnostics and increased awareness of anemia-related conditions have led to more accurate and early diagnosis of anemia. This, in turn, drives the demand for appropriate treatments, including ESAs. Clinical practice guidelines issued by medical associations often recommend the use of ESAs for managing anemia in specific patient populations. These guidelines influence treatment decisions and contribute to the demand for ESAs. This factor will accelerate the demand of Global Erythropoietin Stimulating Agents Market.

Download Free Sample Report

Key Market Challenges

Patent Expirations

When the patents for ESA drugs expire, it allows other pharmaceutical companies to develop and market generic or biosimilar versions of these drugs. This increased competition can lead to a reduction in the price of ESAs as generic or biosimilar products are typically priced lower than the original branded versions. According to a 2024 article, cancer remains a leading global cause of death, responsible for nearly 10 million deaths in 2020. Common types include breast, lung, colorectal, and prostate cancers. Major risk factors include tobacco use, obesity, alcohol, poor diet, inactivity, and air pollution. Infections like HPV and hepatitis cause 30% of cancers in lower-income countries. The expiration of patents can result in the erosion of market share for the original ESA manufacturers. Generic and biosimilar versions can capture a significant portion of the market, particularly if they are more competitively priced. The entry of generic and biosimilar competitors often leads to price erosion in the ESA market. Lower prices can impact the revenue and profitability of the original ESA manufacturers. ESA drugs have historically been high-revenue products for pharmaceutical companies, and their patent expirations can lead to a decline in sales revenue for these companies. The ESA market can become fragmented with multiple generic and biosimilar competitors offering similar products. This fragmentation can lead to pricing pressures and increased competition. The competitive pressure resulting from patent expirations may reduce the incentive for original manufacturers to invest in further research and development for ESA products, potentially slowing down innovation in the field. Patent expirations can impact market access and pricing strategies. Manufacturers may need to adjust their pricing and access strategies to remain competitive in the market. While patent expirations can benefit healthcare systems by reducing the cost of ESA therapy, they can also pose challenges in terms of ensuring patient safety and the appropriate use of biosimilar products.

Changing Treatment Paradigms

As medical knowledge advances, new treatment modalities may emerge that reduce the reliance on ESAs. For example, advances in the management of chronic kidney disease (CKD) or cancer-related anemia might involve alternative approaches such as improved nutrition, iron supplementation, or targeted therapies that address the underlying causes of anemia. Evolving treatment paradigms may lead to a reevaluation of the risk-benefit profile of ESAs. For instance, concerns about ESA safety, such as an increased risk of cardiovascular events, have led to changes in guidelines and recommendations. Healthcare providers may become more cautious in prescribing ESAs in certain situations. Personalized medicine and genetics research can lead to the development of treatment plans tailored to individual patients. In some cases, this may result in a reduced need for ESAs if anemia can be managed through other means or if alternative treatments are more effective for specific patient profiles. Evolving treatment paradigms may emphasize multimodal or combination therapies. In some cases, ESAs may still play a role, but they may be used in conjunction with other treatments, such as iron supplementation or erythropoiesis-stimulating agents with different mechanisms of action. Changes in treatment paradigms often consider cost-effectiveness considerations. Healthcare systems may opt for treatment strategies that are more cost-effective, which could affect the utilization of ESAs. Clinical practice guidelines issued by medical associations may evolve to reflect changes in treatment paradigms and the availability of new treatment options. These guidelines influence treatment decisions and can impact ESA utilization.

Key Market Trends

Shift Toward Epoetin Biosimilars

Biosimilars are biologic drugs that are highly like an already approved reference biologic (in this case, Epoetin) with no clinically meaningful differences in terms of safety and efficacy. The development and approval of biosimilars have been significant in the ESA market. Epoetin biosimilars are often priced lower than the original branded Epoetin products. This cost advantage makes them an attractive option for healthcare systems and providers looking to contain healthcare expenditures while maintaining the quality of care. The introduction of biosimilar versions of Epoetin has increased competition in the ESA market. This competition can lead to reduced prices and increased accessibility of ESA therapies for patients. The availability of Epoetin biosimilars has the potential to expand access to ESA therapy, particularly in regions or healthcare systems where cost considerations may have limited access to the original branded products. The adoption of Epoetin biosimilars can result in substantial healthcare cost savings for both patients and healthcare providers, which is particularly important in regions with budget constraints. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved Epoetin biosimilars based on rigorous comparability assessments. This regulatory approval has increased confidence in their safety and efficacy. Over time, healthcare providers and patients have become more accepting of biosimilars as they gain more experience with their use and as real-world evidence supports their effectiveness and safety.

Segmental Insights

Type Insights

In 2024, the Global Erythropoietin Stimulating Agents Market largest share was held by Epoetin Alfa segment in the forecast period and is predicted to continue expanding over the coming years. Epoetin Alfa, marketed under various brand names, was one of the first ESA products to be introduced to the market. Its early entry allowed it to establish a strong foothold and build trust among healthcare providers. Epoetin Alfa had a long history of use in clinical practice. Healthcare professionals were familiar with its safety and efficacy profile, which contributed to its widespread adoption. Clinical guidelines and recommendations from medical associations often included Epoetin Alfa as a preferred or standard treatment option for managing anemia in specific patient populations. Some physicians may have developed preferences for Epoetin Alfa based on their clinical experiences and familiarity with the product.

Download Free Sample Report

Regional Insights

The North America region dominate the Global Erythropoietin Stimulating Agents Market in 2024. North America, particularly the United States and Canada, boasts a well-developed healthcare infrastructure with advanced medical facilities, a high standard of care, and easy access to healthcare services. This infrastructure facilitates the prescription, administration, and monitoring of ESA therapies. Chronic kidney disease (CKD) and cancer are two of the most common conditions necessitating ESA treatment to manage anemia. North America has a relatively high prevalence of both CKD and cancer, leading to a significant patient population requiring ESA therapy. The United States is home to many pharmaceutical and biotechnology companies with the capability to develop, manufacture, and distribute ESA products. These companies have the resources and expertise to support ESA therapy in the region.

Recent Developments

• According to a 2025 published article titled "Survival and Quality of Life in Patients with Lower-Risk Myelodysplastic Syndromes Exposed to Erythropoiesis-Stimulating Agents: An Observational Cohort Study", treatment with erythropoiesis-stimulating agents (ESAs) was associated with improved survival and enhanced quality of life in patients with lower-risk myelodysplastic syndromes. The study highlights the potential benefits of ESAs in managing anemia and reducing transfusion dependence in this patient population.
• Acording to a 2024 article, Luspatercept and erythropoiesis-stimulating agents (ESAs) showed improved efficacy in treating VEXAS syndrome, both with and without coexisting myelodysplastic syndromes (MDS). These treatments helped manage anemia and reduced transfusion needs, offering promising therapeutic options for patients with this rare autoinflammatory condition.
• In October 2023, Sun Pharmaceutical Industries Ltd. and Zydus Lifesciences Ltd. partnered to co-market Desidustat, an oral treatment for anemia in chronic kidney disease patients in India. This alliance aims to promote an innovative alternative to conventional injectable therapies, enhancing patient convenience and compliance. By introducing Desidustat, the companies intend to reshape anemia management in CKD, offering a more accessible and patient-friendly solution. The collaboration underscores a strategic move to modernize treatment approaches in the Indian healthcare landscape.
• In July 2020, A phase III trial is being conducted to see if efepoetin alfa delivered subcutaneously is as efficient and well tolerated as subcutaneous Mircera for the treatment and maintenance of anaemia in CKD patients not receiving dialysis. An 8-week evaluation phase will be used to gauge the effectiveness of the corrective treatment after a 20-week correction period for dosage titration and Hb correction. To determine long-term safety and maintenance effect, subjects who respond to efepoetin alfa (defined as an increase in Hb 1.0 g/dL versus baseline and Hb level within 10 - 12 g/dL range without blood transfusion during the 28 weeks after the first dose) will be randomly assigned to receive subcutaneous efepoetin alfa once every 2W or once every 4W for an additional 24-week extension period.
• In February 2020, A Phase III clinical research on the effectiveness of intravenous iron injection, Ferinject, in cancer patients with anaemia was started at Samsung Medical Centre as part of a multicenter randomised investigation.

Key Market Players

• Amgen Inc.
• Biocon Limited
• Celltrion Inc.
• F. Hoffmann-La Roche Ltd
• Intas Pharmaceuticals Ltd
• Johnson and Johnson
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Thermo Fisher Scientific
• LG Lifesciences, Ltd
• Novartis AG(Sandoz)
• Panacea Biotec Ltd

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•  Erythropoietin Stimulating Agents Market, By Type:

o    Epoetin Alfa

o    Epoetin Beta

o    Darbepoetin Alfa

o    Other Types

•  Erythropoietin Stimulating Agents Market, By Application:

o    Cancer

o    Renal Disorders

o    Anti-retroviral Treatment

o    Neural Diseases

o    Other Applications

• Erythropoietin Stimulating Agents Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

Global Erythropoietin Stimulating Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Erythropoietin Stimulating Agents Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]